Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China

Wu, Jian; Wang, Yuan; Cai, Zhen; Lin, Zechen; Huang, Haijun; Wang, Dawei; Yu, Jiong; Jiang, Bin; Zhao, Xinguo; Zhai, Guangju; Lin, Shengyou; Li, Lanjuan; Cao, Hong

doi:10.1155/2022/7009876

Cited by 4 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 they recommend timely TCM-WM to COVID-19 therapy. 33 Our findings are important complements to the previous works, indicating that VD3 is also a feasible adjuvant therapy for COVID-19.…”

Section: Discussionsupporting

confidence: 84%

“…identifies that traditional Chinese medicine and Western medicine combination (TCM‐WM) has better performance in terms of both the progression and outcome of severe COVID‐19 patients, compared to single Western medicine treatment, and they recommend timely TCM‐WM to COVID‐19 therapy. 33 Our findings are important complements to the previous works, indicating that VD3 is also a feasible adjuvant therapy for COVID‐19.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Vitamin D3 attenuates SARS‐CoV‐2 nucleocapsid protein‐caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR‐BRCC3 signaling pathway in vitro and in vivo

Chen

et al. 2023

MedComm

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection‐caused coronavirus disease 2019 (COVID‐19) is a global crisis with no satisfactory therapies. Vitamin D3 (VD3) is considered a potential candidate for COVID‐19 treatment; however, little information is available regarding the exact effects of VD3 on SARS‐CoV‐2 infection and the underlying mechanism. Herein, we confirmed that VD3 reduced SARS‐CoV‐2 nucleocapsid (N) protein‐caused hyperinflammation in human bronchial epithelial (HBE) cells. Meanwhile, VD3 inhibited the NOD‐like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation in N protein‐overexpressed HBE (HBE‐N) cells. Notably, the inhibitors of caspase‐1, NLRP3, and NLRP3 or caspase‐1 small interference RNA (siRNA) enhanced VD3‐induced NLRP3 inflammasome inactivation, with subsequent suppression of interleukin‐6 (IL6) and IL1β release in HBE‐N cells, which were abolished by the NLRP3 agonist. Moreover, VD3 increased NLRP3 ubiquitination (Ub‐NLRP3) expression and the binding of the VDR with NLRP3, with decreased BRCA1/BRCA2‐containing complex subunit 3 (BRCC3) expression and NLRP3‐BRCC3 association. VD3‐induced Ub‐NLRP3 expression, NLRP3 inflammasome inactivation, and hyperinflammation inhibition were improved by the BRCC3 inhibitor or BRCC3 siRNA, which were attenuated by the vitamin D receptor (VDR) antagonist or VDR siRNA in HBE‐N cells. Finally, the results of the in vivo study in AAV‐Lung‐enhanced green fluorescent protein‐N‐infected lungs were consistent with the findings of the in vitro experiment. In conclusion, VD3 attenuated N protein‐caused hyperinflammation by inactivating the NLRP3 inflammasome partially through the VDR‐BRCC3 signaling pathway.

show abstract

“…4 they recommend timely TCM-WM to COVID-19 therapy. 33 Our findings are important complements to the previous works, indicating that VD3 is also a feasible adjuvant therapy for COVID-19.…”

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 83%

Vitamin D3 attenuates SARS‐CoV‐2 nucleocapsid protein‐caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR‐BRCC3 signaling pathway in vitro and in vivo

Chen

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…AKI is an increasingly frequent disease as part of acute kidney disease, defined clinically as a rapid loss of kidney function ( Liu et al, 2020 ; Shaoxiong et al, 2022 ), which can be fatal if not treated promptly ( Geng et al, 2021 ). AKI has been reported to be a common complication in hospitalized and critically ill patients ( Vijayan et al, 2021 ), and it can be induced by a variety of risk factors, such as sepsis, cirrhosis, acute pancreatitis, cancer, chronic kidney disease, COVID-19, and cardiac surgery ( Campbell et al, 2014 ; Gaffney and Sladen, 2015 ; Nassar and Qunibi, 2019 ; Gupta et al, 2021 ; Kuwabara et al, 2022 ; Wu et al, 2022 ). These risk factors can lead to the development of AKI with a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Development and application of an amplified luminescent proximity homogeneous assay-linked immunosorbent assay for the accurate quantification of kidney injury molecule-1

Fu,

Sun,

Qin

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Background: Kidney injury molecule-1 (Kim-1), a specific marker of kidney injury, is usually not expressed in normal kidneys or at very low levels but is highly expressed in injured renal tubular epithelial cells until the damaged cells recover completely. Therefore, we aimed to develop an efficient and highly sensitive assay to accurately quantify Kim-1 levels in human serum and urine.Methods: In this study, a novel immunoassay was developed and named amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). Anti-Kim-1 antibodies can be directly coupled to carboxyl-modified donor and acceptor beads for the rapid detection of Kim-1 by double-antibody sandwich method. Serum and urine samples for Kim-1 measurements were obtained from 129 patients with nephropathy and 17 healthy individuals.Results: The linear range of Kim-1 detected by AlphaLISA was 3.83–5000 pg/mL, the coefficients of variation of intra-assay and inter-assay batches were 3.36%–4.71% and 5.61%–11.84%, respectively, and the recovery rate was 92.31%–99.58%. No cross reactions with neutrophil gelatinase-associated lipocalin, liver-type fatty acid binding protein, and matrix metalloproteinase-3 were observed. A good correlation (R2 = 0.9086) was found between the findings of Kim-1-TRFIA and Kim-AlphaLISA for the same set of samples. In clinical trials, both serum and urine Kim-1 levels were significantly higher in patients with nephropathy than in healthy individuals, especially in patients with acute kidney injury. Furthermore, serum Kim-1 was superior to urinary Kim-1 in distinguishing between patients with nephropathy and healthy individuals.Conclusion: The developed Kim-1-AlphaLISA is highly efficient, precise, and sensitive, and it is suitable for the rapid detection of patients with acute kidney injury.

show abstract

“…2019 novel coronavirus pneumonia (COVID-19) is an acute infectious disease caused by a novel coronavirus strain classified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ( Andersen et al., 2020 ; Wu et al, 2022 ). The disease is highly infectious and seriously threatens human life ( Qin et al,.…”

Section: Introductionmentioning

confidence: 99%

Serum hyaluronic acid and procollagen III, N-terminal propeptide levels are highly associated with disease severity and predict the progression of COVID-19

Yang,

Liu,

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic is a rapidly evolving global emergency and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. In order to early identify severe and critical patients, we retrospectively analyze the clinical characteristics and risk indicators of severe disease in patients with corona virus disease 2019 (COVID-19).MethodsA total of 420 confirmed COVID-19 patients were included in the study. According to the “Diagnosis and Treatment of novel coronavirus Pneumonia (10th Edition)”, the cases were divided into mild group (n = 243) and severe group (n =177). Laboratory parameters were analyzed in combination with clinical data.ResultsMale patients over 46 years who have smoking habits were more likely to suffer from severe COVID-19. Critically ill patients had lower lymphocyte counts and red blood cell counts, and higher white blood cell counts (P<0.05). Expectedly, serum inflammatory factors (NLR, PLR, LMR, CLR, PCT, CRP), coagulation markers (APTT, PT, TT, FIB, D-Dimer), Myocardial damage markers (hs-TNT, LDH) were significantly increased (P<0.05) in severe COVID-19 patients. Surprisedly, those patients showed obviously elevated levels of common tumor markers (ProGRP, CYFRA21-1, SCC, NSE) (P<0.05). In this case, the levels of tumor marker reflected more the condition of inflammation than the growth of tumor. More importantly, HA and PIIIN-P were highly associated with COVID-19 severity. The AUC of the ROC curve for the diagnosis of severe COVID-19 by HA and PIIIN-P was 0.826. Meanwhile, HA was positively correlated with myocardial damage markers (hs-TNT, LDH). PIIIN-P was positively correlated with myocardial damage markers (hs-TNT, LDH) and inflammatory factors (NLR, PLR, LMR, CLR, ProGRP, SCC, PCT, CRP). On the contrary, PIIIN-P was negatively correlated with pulmonary function indexes (oxygenation index and oxygen saturation of hemoglobin).ConclusionHA and PIIIN-P are highly associated with disease severity and progression of COVID-19 and can be used as new markers for the prediction of severe COVID-19.

show abstract

Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China

Cited by 4 publications

References 28 publications

Vitamin D3 attenuates SARS‐CoV‐2 nucleocapsid protein‐caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR‐BRCC3 signaling pathway in vitro and in vivo

Vitamin D3 attenuates SARS‐CoV‐2 nucleocapsid protein‐caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR‐BRCC3 signaling pathway in vitro and in vivo

Development and application of an amplified luminescent proximity homogeneous assay-linked immunosorbent assay for the accurate quantification of kidney injury molecule-1

Serum hyaluronic acid and procollagen III, N-terminal propeptide levels are highly associated with disease severity and predict the progression of COVID-19

Contact Info

Product

Resources

About